Form 4 for MIRM Mirum Pharmaceuticals, Inc.
Accepted 2026-06-09 21:21:05 ET · period of report 2026-06-08 · accession 0001197350-26-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-06-09 21:21 | 2026-06-08 | MIRM | BJERKHOLT ERIC | CFO | S - Sale+OE | $93.82 | -5,000 | 44.8K | -10% | -$469.1K |
| DT | 2026-06-09 21:21 | 2026-06-09 | MIRM | BJERKHOLT ERIC | CFO | M - OptEx | $26.49 | +2,393 | 47.2K | +5% | +$63.4K |
| DT | 2026-06-09 21:21 | 2026-06-09 | MIRM | BJERKHOLT ERIC | CFO | M - OptEx | $0.00 | -2,393 | 26.7K | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-08 | S | D | 2,258 | $92.84 | 47,530 | D | — | — | (F1) Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026. (F2) . The weighted average sale price for the transaction reported was $92.84, and the range of prices were between $92.485 and $93.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 2 | Common | Common Stock | 2026-06-08 | S | D | 1,175 | $93.95 | 46,355 | D | — | — | (F1) Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026. (F3) . The weighted average sale price for the transaction reported was $93.95, and the range of prices were between $93.49 and $94.47. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 3 | Common | Common Stock | 2026-06-08 | S | D | 1,567 | $95.12 | 44,788 | D | — | — | (F1) Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026. (F4) . The weighted average sale price for the transaction reported was $95.12, and the range of prices were between $94.62 and $95.44. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 4 | Common | Common Stock | 2026-06-09 | M | A | 2,393 | $26.49 | 47,181 | D | — | — | |
| 5 | Derivative | Employee Stock Option (right to buy) | 2026-06-09 | M | D | 2,393 | $0.00 | 26,653 | D | $26.49 · — to 2034-01-22 | 2,393 Common Stock | (F5) 1/4th of the shares vested one year after January 23, 2024 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. |